Mark W. Womack is BioCina’s Chief Executive Officer, and in his first 9 months at the helm he led BioCina to a 500% YOY increase in sales and a 250% YOY increase in revenue. Mark is an organization builder with a track record of delivering unprecedented growth and profit in every role.

Prior to BioCina, Mark was CEO of KBI Biopharma and Selexis SA, and previous to that, he was CEO and Managing Director of Stelis Biopharma, leading both to significant YOY growth. Preceding Stelis, as the CBO for AGC Biologics, one of the world’s leading global biopharma CDMO’s, he led them to nearly a 300% increase in new sales in just two years. Prior to joining AGC Biologics, Mark served over 20 years as an international management consulting industry leader, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. This included a $20B post-merger integration within General Motors.

Mark began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship, and he received numerous of the Navy’s highest honors and awards.

Mark has been quoted as a key source in The New York Times, Fast Company and numerous other major global media outlets.